ANDA 65369, held by Hospira Inc. Cefepime Hydrochloride.
As of Nov 16, 2026, ANDA 65369 (Cefepime Hydrochloride), held by Hospira Inc, was first approved by FDA on Jun 18, 2007, with 3 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 18, 2007 | Original application | Approved |
| Cefepime HydrochlorideEQ 500MG BASE/VIAL · injectable;injection | Cefepime Hydrochloride | Discontinued |
| Cefepime HydrochlorideEQ 1GM BASE/VIAL · injectable;injection | Cefepime Hydrochloride | Discontinued |
| Cefepime HydrochlorideEQ 2GM BASE/VIAL · injectable;injection | Cefepime Hydrochloride | Discontinued |
| Sep 29, 2011 | Supplement 10Labeling | Approved | None posted |
| May 27, 2008 | Supplement 4Labeling | Approved | None posted |
| Feb 7, 2008 | Supplement 2Labeling | Approved | None posted |
| Jun 18, 2007 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters